Tislelizumab

B-NHL

Ruijin Hospitalmonoclonal_antibodyPhase 2Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 38/ 100
Competitive Position: 95/ 100

Competitive context

316 Active assets in the B-NHL cohort.

Asset / Sponsor	Phase	Rating
VINDESINE Children's Cancer Group, China	Phase 4	BBB
cc-5013 Shanghai Junshi Bioscience Co., Ltd.	Phase 4	BBB
Odronextamab University of Birmingham	Phase 3	BBB
METHOTREXATE Children's Cancer Group, China	Phase 4	BBB
Cytosin-Arabinosid Children's Cancer Group, China	Phase 4	BBB

View all 50 →

Same molecule, other indications

Tislelizumab is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

69 / 100

Hepatic Metastasis of Pancreatic CancerDormant

BB

Indicative ·

69 / 100

Primary Peritoneal Cavity CancerDormant

BB

Indicative ·

68 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.